GlassScriptPhysician profile
Majd Alnas
NPI 1396944658
$8,412.11
in general payments reported to CMS, 2019-2025
18 companies · $756 in 2025
The $756 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $391 · 2021: $980 · 2022: $869 · 2023: $3,236 · 2024: $1,772 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,109 · Food and Beverage: $1,737 · Travel and Lodging: $918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,109.19 |
| Food and Beverage | $1,736.85 |
| Travel and Lodging | $918.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,000.00 | 2023 | Ion |
| Pulmonx Corporation | $1,145.41 | 2024 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Mylan Specialty L.P. | $742.96 | 2019-2024 | Yupelri |
| Glaxosmithkline, LLC. | $558.86 | 2019-2025 | Nucala, Trelegy Ellipta |
| Inspire Medical Systems, INC. | $526.04 | 2022-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $489.46 | 2019-2023 | Ofev |
| Astrazeneca Pharmaceuticals LP | $441.68 | 2019-2024 | Airsupra, Breztri |
| Genzyme Corporation | $401.64 | 2021-2024 | |
| Harmony Biosciences LLC | $275.16 | 2024-2025 | |
| Philips North America LLC | $239.28 | 2019-2025 | Vest Therapy Und |
| Regeneron Healthcare Solutions, INC. | $212.72 | 2021-2023 | Dupixent |
| Abbvie INC. | $101.19 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $96.25 | 2019-2020 | |
| Amgen INC. | $59.04 | 2024 | Tavneos |
| Insmed, INC. | $53.82 | 2025 | Arikayce, Brinsupri |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $35.55 | 2020 | |
| Viatris Specialty LLC | $19.85 | 2025 | Yupelri |
| Shionogi INC | $13.20 | 2024 | Fetroja |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Majd Alnas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.